Last reviewed · How we verify
Azacitidine combined HHT
Azacitidine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while HHT (homoharringtonine) inhibits protein synthesis to induce apoptosis in leukemic cells.
Azacitidine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while HHT (homoharringtonine) inhibits protein synthesis to induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS).
At a glance
| Generic name | Azacitidine combined HHT |
|---|---|
| Also known as | Azacitidine+HHT |
| Sponsor | Shandong Provincial Hospital |
| Drug class | Hypomethylating agent combined with protein synthesis inhibitor |
| Target | DNA methyltransferase (DNMT) and eukaryotic translation elongation factor 2 (eEF-2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Azacitidine is a hypomethylating agent that reverses aberrant DNA methylation in myelodysplastic and hematologic malignancies, restoring expression of tumor suppressors. Homoharringtonine (HHT) is a natural alkaloid that inhibits translation elongation, triggering apoptosis particularly in leukemic blasts. The combination targets both epigenetic dysregulation and protein synthesis, providing complementary mechanisms against hematologic malignancies.
Approved indications
- Acute myeloid leukemia (AML)
- Myelodysplastic syndrome (MDS)
Common side effects
- Myelosuppression/neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Nausea/vomiting
- Fatigue
Key clinical trials
- New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (PHASE2)
- VAH vs VA in Newly Diagnosed Elderly AML (PHASE3)
- Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. (PHASE2)
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (PHASE1, PHASE2)
- Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML (PHASE2)
- HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML (PHASE2)
- HVA vs IA/DA or VA in the Treatment of ND HR-AML (PHASE3)
- Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azacitidine combined HHT CI brief — competitive landscape report
- Azacitidine combined HHT updates RSS · CI watch RSS
- Shandong Provincial Hospital portfolio CI